Loading... Please wait...
Sort by:
  • Breast Cancer: Update Bulletin [December 2014]
    Learn More Breast Cancer: Update Bulletin [December 2014]
    Gain new KOL insights on the latest events happening in Breast Cancer: Pfizer’s cyclin-dependent kinase (CDK) inhibitor palbociclib; PALOMA-1 trial; Novartis’ LEE011 and Eli Lilly’s...
  • Colorectal Cancer: Update Bulletin [November 2014]
    Learn More Colorectal Cancer: Update Bulletin [November 2014]
    Gain new KOL insights on the latest events happening in Colorectal Cancer: ESMO 2014, Taiho Oncology’s TAS-102, RECOURSE trial; Mologen’s MGN 1703, IMPACT and IMPALA trials; XBiotech’s Xilonix,...
  • HIV: KOL Insight
    Learn More HIV: KOL Insight
    HIV: KOL Insight examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into what's driving long term...
  • Diabetes: Update Bulletin [November 2014]
    Learn More Diabetes: Update Bulletin [November 2014]
    Gain new KOL insights on the latest events happening in Diabetes: Bydureon Pen; phase III data of Intarcia’s ITCA 650, AdCom, Saxenda (liraglutide 3mg), phase III results for omarigliptin and trelagliptin...
  • Non-Small Cell Lung Cancer: Update Bulletin [November 2014]
    Learn More Non-Small Cell Lung Cancer: Update Bulletin [November 2014]
    Gain new KOL insights on the latest events happening in Non-Small Cell Lung Cancer: ESMO 2014; AstraZeneca’s MEDI4736 and AZD9291, LUX-Lung 8 trial of Boehringer Ingelheim’s Gilotrif versus...
  • COPD: Update Bulletin [November 2014]
    Learn More COPD: Update Bulletin [November 2014]
    Gain new KOL insights on the latest events happening in COPD: triple fixed-dose combination products, the WISDOM trial (steroid withdrawal) results, tiotropium/olodaterol and the potential role of anti-IL5 antibodies in...
  • Rheumatoid Arthritis: Update Bulletin [October 2014]
    Learn More Rheumatoid Arthritis: Update Bulletin [October 2014]
    Gain new KOL insights on the latest events happening in Rheumatoid Arthritis: Roche’s RoACTEMRA (tocilizumab), Janssen Biologics’ golimumab (Simponi), anti-IL6 monoclonals sarilumab and sirukumab; Xeljanz,...
  • Hepatitis C: Payer Insights
    Learn More Hepatitis C: Payer Insights
    The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives.  Payer Insights: Hepatitis C, based on in-depth interviews...
  • HIV: Update Bulletin [August 2014]
    Learn More HIV: Update Bulletin [August 2014]
    Gain new KOL insights on the latest events happening in HIV: ViiV Healthcare’s Tivicay and Triumeq, Merck & Co.’s, Isentress, raltegravir/lamivudine, Gilead’s Vitekta, Tybost, Janssen,...
  • Breast Cancer: Update Bulletin [August 2014]
    Learn More Breast Cancer: Update Bulletin [August 2014]
    Gain new KOL insights on the latest events happening in Breast Cancer: ALTTO, ExteNET, BOLERO-2, PALOMA-1 trials, GlaxoSmithKline’s Tykerb, Novartis’ Afinitor, Pfizer, Puma’s neratinib,...
  • Diabetes: Update Bulletin [August 2014]
    Learn More Diabetes: Update Bulletin [August 2014]
    Gain new KOL insights on the latest events happening in Diabetes: Toujeo, Eli Lilly/Boehringer Ingelheim’s Abasria, Novo Nordisk’s Xultophy/IDegLira, peglispro Highlights from this event update...
  • Colorectal Cancer: Update Bulletin [August 2014]
    Learn More Colorectal Cancer: Update Bulletin [August 2014]
    Gain new KOL insights on the latest events happening in Colorectal Cancer: ASCO 2014, Vectibix, metastatic CRC (mCRC), ASPECCT, CALGB 80405 study results, TAS-102 Highlights from this event update...
  • Hepatitis C: Update Bulletin [August 2014]
    Learn More Hepatitis C: Update Bulletin [August 2014]
    Gain new KOL insights on the latest events happening in Hepatitis C: Janssen-Cilag/Medivir; Olysio; Gilead; sofosbuvir; ledipasvir; AbbVie; 3D combination; access to new HCV therapies Highlights from this event...
  • Chronic Lymphocytic Leukaemia: Update Bulletin [July 2014]
    Learn More Chronic Lymphocytic Leukaemia: Update Bulletin [July 2014]
    Gain new KOL insights on the latest events happening in Chronic Lymphocytic Leukaemia: GSK/Genmab’s Arzerra; Roche’s Gazyvaro, ABT-199; Pharmacyclics/Janssen’s Imbruvica Highlights from this event...
  • Non-Small Cell Lung Cancer: Update Bulletin [July 2014]
    Learn More Non-Small Cell Lung Cancer: Update Bulletin [July 2014]
    Gain new KOL insights on the latest events happening in Non-Small Cell Lung Cancer: ASCO 2014, T790M-mediated endothelial, EGFR, AstraZeneca’s AZD-9291, Clovis’ CO-1686, Novartis’ Zykadia,...
  • Rheumatoid Arthritis: Update Bulletin [June 2014]
    Learn More Rheumatoid Arthritis: Update Bulletin [June 2014]
    Gain new KOL insights on the latest events happening in Rheumatoid Arthritis: European Medicines Agency (EMA) approves Roche's subcutaneous formulation of tocilizumab (RoACTEMRA) Highlights from this event update...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved